Association of cord blood methylation with neonatal leptin: An epigenome wide association study

Rachel Kadakia¹*, Yinan Zheng², Zhou Zhang², Wei Zhang², Jami L. Josefson¹‡, Lifang Hou²‡

¹ Division of Endocrinology, Ann and Robert H. Lurie Children’s Hospital of Chicago and Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America, ² Center for Population Epigenetics, Robert H. Lurie Comprehensive Cancer Center and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America

‡ Co-senior authors
* rkadakia@luriechildrens.org

Abstract

Background
Neonatal adiposity is a risk factor for childhood obesity. Investigating contributors to neonatal adiposity is important for understanding early life obesity risk. Epigenetic changes of metabolic genes in cord blood may contribute to excessive neonatal adiposity and subsequent childhood obesity. This study aims to evaluate the association of cord blood DNA methylation patterns with anthropometric measures and cord blood leptin, a biomarker of neonatal adiposity.

Methods
A cross-sectional study was performed on a multiethnic cohort of 114 full term neonates born to mothers without gestational diabetes at a university hospital. Cord blood was assayed for leptin and for epigenome-wide DNA methylation profiles via the Illumina 450K platform. Neonatal body composition was measured by air displacement plethysmography. Multivariable linear regression was used to analyze associations between individual CpG sites as well as differentially methylated regions in cord blood DNA with measures of newborn adiposity including anthropometrics (birth weight, fat mass and percent body fat) and cord blood leptin. False discovery rate was estimated to account for multiple comparisons.

Results
247 CpG sites as well as 18 differentially methylated gene regions were associated with cord blood leptin but no epigenetic changes were associated with birth weight, fat mass or percent body fat. Genes of interest identified in this study are DNAJA4, TFR2, SMAD3, PLAG1, FGF1, and HNF4A.
Conclusion

Epigenetic changes in cord blood DNA are associated with cord blood leptin levels, a measure of neonatal adiposity.

Introduction

Adiposity at birth may be a predictor of obesity in childhood and adulthood.[1] Obesity has a current estimated prevalence of 17% among children aged 2–19 and has become increasingly challenging to treat once present.[2] Obesity related co-morbidities, such as type 2 diabetes and metabolic syndrome are now occurring earlier and more frequently in individuals with early life obesity.[3, 4] The etiology of obesity is complex, multifactorial, and includes genetic, nutritional, and environmental determinants. Researchers studying the developmental origins of health and disease have proposed that the intrauterine environment of the developing fetus contributes to adipose tissue deposition via fetal programming, suggesting that obesity risk is present before birth.[5, 6]

Epigenetics, the study of modifications to DNA that alter gene expression without changing gene sequence, is one mechanism contributing to the early life development of excess adiposity and future risk of an adverse metabolic phenotype.[7] Aberrant methylation of CpG dinucleotides in DNA is a type of epigenetic modification that can be both heritable and modifiable by one’s environment. Prenatal exposures, maternal pregnancy characteristics, and the intrauterine milieu can alter susceptibility of neonatal DNA to methylation, leading to changes in the child’s gene expression, gene regulation, and metabolic risk.[8, 9] Prior studies have demonstrated associations between maternal phenotypes and offspring DNA methylation, supporting the hypothesis that the intrauterine environment impacts fetal epigenetics.[10–12] Methylation patterns present at birth which are associated with newborn adiposity or later childhood obesity suggest that epigenetics may be partially responsible for the perinatal origins of obesity risk and predict future obesity. Identifying DNA methylation patterns associated with perinatal adiposity measures is one potential tool that can be used to detect high risk individuals early in life, a critical time point for early intervention before obesity develops.

Several research groups have identified epigenetic changes associated with newborn size; however many of these studies have used a targeted approach, only examining specific genes of interest such as HIF3A and AHRR.[13, 14] Studies that have previously taken an epigenome wide approach performed associations with indirect measures of newborn adiposity, such as birth weight.[15] Replication of specific epigenetic changes within independent cohorts are limited.

In this study, we evaluated the relationship between cord blood methylation patterns and markers of neonatal adiposity in a cohort of healthy, full-term infants born to mothers with normal glucose tolerance. Maternal hyperglycemia, even below the diagnostic threshold for gestational diabetes, is a well described risk factor for neonatal adiposity; therefore, elimination of this known confounder is key when investigating adiposity contributors.[16] We utilized an epigenome wide approach to examine differentially methylated regions in cord blood DNA and their association with newborn anthropometrics (birth weight, fat mass, and percent body fat) as well as cord blood leptin levels, a biomarker of neonatal adiposity with the aim to identify both novel and previously described epigenotype-phenotype relationships [8, 9, 11–15]. We hypothesize that cord blood epigenetic changes will be associated with measures of
neonatal adiposity such as percent body fat, fat mass, and cord blood leptin, and provide insight into early life mechanisms of future obesity risk.

Materials and methods

Subjects

Our study population consisted of a cohort of 114 healthy maternal-neonatal pairs on whom cord blood DNA was available. Participants were recruited from 2011–2014 at a large academic medical center in Chicago, Illinois, USA as previously described in detail.[17] Women carrying a singleton pregnancy with normal glucose tolerance on a fasting two-hour 75g OGTT performed between 24 and 28 weeks gestation were eligible for the study.[18] Women were excluded if they had a history of greater than 3 term pregnancies, were on chronic medications such as glucocorticoids, insulin, or anti-hypertensives, or smoked during pregnancy, as these factors can be associated with excess or restricted growth.[19] Newborns were full-term and excluded if they required intensive care, were too ill to undergo body composition measurements within the first 24–72 hours of life, or had congenital anomalies, as some of these are independently associated with abnormal fetal growth. Cord blood was collected after birth by labor and delivery staff and processed within 30 minutes. Cord blood to be used for DNA extraction and future leptin assays was stored at -70˚C until laboratory assays were performed. 115 maternal neonatal pairs were initially included in the study; one pair was excluded due to poor DNA quality. Of the 114 neonates included in the final analysis, 105 had body composition data available. This study was approved by the Northwestern University Institutional Review Board and each mother provided written informed consent for herself and her neonate at the time of study enrollment.

Body composition measurements

Body composition measurements of each neonate occurred between 24–72 hours of life and were obtained in duplicate by one of two trained examiners. Length was obtained using a hard-surface measuring board. Measurements were recorded to the nearest 0.1cm, performed in duplicate, and the results averaged for the final research measure. Weight and adiposity measurements were obtained by method of air displacement plethysmography (PeaPod, Cosmed, Rome, Italy), a noninvasive, nonuser dependent modality that has been validated in comparison with deuterium dilution in full-term infants between ages 0.4–21.7 weeks and of weight 2–8 kg.[20, 21] To measure weight, the infant was undressed and placed on the calibrated PeaPod scale and weight was recorded to the nearest 0.0001 kg. Next, the infant was placed inside the PeaPod volume chamber for two minutes to determine body volume. Density was calculated after which age- and sex-specific fat-free mass density values were used to determine absolute fat-free mass and fat mass. Percent body fat was subsequently calculated from these values.[21]

Laboratory measurements

Samples for leptin were batched and measured in duplicate with a radioimmunoassay kit (Millipore Corp, Billerica, MA, USA). The inter- and intra-assay coefficients of variation for leptin were 3.7–5.9% and 3.0–4.0%, respectively.

DNA was purified from neonatal cord blood using an Autopure LS Automated DNA Purification System with Autopure reagents (Autogen, Inc., Holliston, MA). The purified DNA samples were stored under -20˚C. DNA quality and quantity were assessed by Nanodrop (ThermoFisher Scientific, MA, USA). Bisulfite conversion was performed on 500 ng of DNA
using the EZ DNA Methylation Kit (Zymo Research, CA, USA). Methylation levels were measured using the Infinium HumanMethylation 450K Beadchip array (Illumina, Inc. CA, USA), which targets ~486,000 CpG sites, in 114 samples that passed DNA quality testing. Samples were randomly plated on each chip with regard to neonatal sex. BeadChips were scanned with an Illumina iScan and analyzed using Illumina GenomeStudio software. All experiments were conducted following manufacturer protocols in the Genomics Core Facility at the Center for Genetic Medicine at Northwestern University.

DNA methylation data processing

Raw Illumina IDAT data were preprocessed per previously published methodology.[10] Briefly, one DNA sample containing more than 5% of CpG probes with detection p-values greater than 0.01, as well as 191 CpG probes that were not detectable (detection p-value > 0.01) in more than 5% of samples were removed during quality control. We further removed 65 built in SNP probes, 3,091 non-CpG probes, 36,535 probes containing proximal SNPs, and 11,648 probes on sex chromosomes. Signal intensities of the filtered probes were corrected for background noise and channel color bias. There were 434,506 CpG sites used in the final analysis. Methylated and unmethylated intensities were then quantile-normalized and corresponding β values were calculated (i.e., the proportion of methylated probe intensity out of total intensity). The function ComBat in R package sva was implemented to the normalized β values to adjust for potential batch effects and then the function sva in the same R package was applied to generate surrogate variables that were used to account for other unwanted variations in the data including the confounding effects of cell type heterogeneity on methylation profiles.[22]

Bioinformatics and statistical analysis

We conducted an epigenome wide association study using previously described methodology.[23] Briefly, linear regression models were used with neonatal adiposity measures as dependent variables and methylation as the variable of interest. Models were adjusted for maternal age at delivery, race, gestational age in days, and infant sex, as these variables can affect neonatal body composition. Two surrogate variables generated by sva were also adjusted. An adjusted p value (FDR) < 0.05 following the Benjamini–Hochberg procedure was considered significant.[24]

We also examined the association of percent body fat, fat mass, and log_{10} transformed cord blood leptin levels with differentially methylated regions (DMRs) using the R package DMRcate.[25] T-statistics of CpG sites from EWAS were smoothed by chromosome using a Gaussian kernel smoothing function with bandwidth λ = 1000 base pairs and scaling factor C = 2. DMRs were assigned by grouping significant CpG sites (FDR < 0.05). We used Stouffer’s method to compute combined FDR as the statistical inference for that region and the mean coefficients from the regression models summarizes the regional effect.[26] Within each DMR identified, given the identical sample size and similar distribution of methylation values across all the adjacent CpGs, we applied an inverse-variance weighting approach to compute the weighted mean of coefficients across the CpGs, weighted by the inverse of the corresponding standard error. The weighted mean coefficients were then re-expressed as percent changes in cord blood leptin levels with every 0.01 methylation β value increase. All analyses were conducted using R software (version 3.3.1).

Regulatory elements

Transcriptional regulations can be controlled by complicated interactions between regulatory elements, such as histone modifications and DMRs. In order to further explore potential
functional implications of differentially methylated regions, we used the Encyclopedia of DNA Elements (ENCODE) Project [27] to find regulatory elements that overlapped or were nearby the significant DMRs. We used DNase I hypersensitivity sites (DNase), transcription factor binding sites (TFBS), and annotations of histone modification ChIP peaks pooled across cell lines (data available in the ENCODE Analysis Hub at the European Bioinformatics Institute http://ftp.ebi.ac.uk/pub/databases/ensembl/encode/integration_data_jan2011/). The hg19 human assembly from Genome Browser was used to provide DMR location information.

Results

Descriptive statistics of the study participants are shown in Table 1. The majority of infants had a birth weight that was appropriate for gestational age and percent body fat of the cohort was normally distributed. 61% of mothers were normal weight while 34% were overweight or obese. No mothers in this cohort smoked during pregnancy.

We did not identify any associations between individual CpG sites or CpG gene regions and % fat, fat mass, or birth weight. When studying methylation of individual CpG sites, we found associations of 247 unique CpG sites with cord blood leptin, a marker of neonatal adiposity. Among them, 177 (72%) were negatively associated with leptin and 70 (28%) were positively associated with leptin (Fig 1, S1 Table). Using the DAVID Functional Annotation Tool (version 6.8) [28, 29], the genes targeted by the 177 negatively associated CpGs were enriched in lipid metabolic process (GO:0006629) (p = 0.0075), the genes targeted by the 70 positively associated CpGs were enriched in regulation of CD8-positive, alpha-beta T cell proliferation (GO:2000564) (p = 0.0077). The top 10 CpG sites are displayed in Table 2 with the remainder.
We also identified DMRs in 18 genes that were associated with cord blood leptin levels. The name and function of each gene, along with the location of each DMR is detailed in Table 3. Increased DMR methylation in 9 of these genes was negatively associated with cord blood leptin levels while hypermethylation in 9 genes demonstrated positive association with leptin. The function or proposed function of all genes is listed; however, 2 genes have not been well studied with regards to their role in disease development.

Increased methylation across 14 CpG sites in the DnaJ heat shock protein family (Hsp40) member A4 (\(DNAJA4\)) gene promoter (chromosome 15, position 78555907 to 78557584, hg19 genome assembly) was negatively associated with cord blood leptin levels (Fig 2). For every 0.01 increase in methylation in this region, neonatal cord blood leptin decreased by 3.2% (FDR adjusted \(p = 0.0114\)). Furthermore, multiple gene regulatory elements were found to overlap with the hypermethylated region (Fig 2). All CpG sites evaluated in the \(DNAJA4\) gene are displayed in S2 Table.

A 0.01 increase in methylation across 4 CpG sites in the Transferrin receptor 2 (\(TFR2\)) gene (chromosome 7, position 100230781 to 100231672) was associated with a 6.2% increase in neonatal cord blood leptin (FDR adjusted \(p = 0.0358\)). These CpG sites are located at the promoter region of one \(TFR2\) transcript (Fig 3). All CpG sites evaluated in the \(TFR2\) gene are displayed in S2 Table. In addition, there are several regulatory elements that overlap with this differentially methylated region (Fig 3). We did not find any differentially methylated regions associated with anthropometric measures of neonatal adiposity.

Fig 1. Manhattan plot. This manhattan plot depicts the CpG sites by chromosome that are associated with cord blood leptin. The dotted line defines a FDR adjusted significance level of < 0.05. The top 10 CpGs sites are identified within the figure.

https://doi.org/10.1371/journal.pone.0226555.g001
This epigenome wide association study demonstrates a relationship between neonatal cord blood leptin levels and 1) 247 individual CpG sites and 2) differentially methylated regions of 18 genes. SMAD3, PLAG1, FGF1, HNF4A, DNAJA4, and TFR2 are six genes identified in this study that have previously been reported in relation to tissue growth and adiposity. We chose to highlight these genes for their potential impact on adipose tissue development.

When evaluating associations between individual CpG sites and cord blood leptin levels, four genes are worth noting. SMAD3 encodes for smad3, a signaling effector that mediates transforming growth factor-beta’s (TGF-beta) inhibition of adipocyte differentiation.[30] We identified that increased methylation at cg03480935 within SMAD3 was associated with decreased cord leptin levels. This finding is unexpected as increased methylation is typically associated with decreased gene expression. In this case, potential decreased expression of SMAD3 would lead to less inhibition of adipocyte differentiation and presumably higher leptin levels.

PLAG1 is a transcription factor whose activation results in upregulation of target genes important for cell proliferation. PLAG1 mutations are associated with lipoblastoma, a benign adipocytic tumor, suggesting its role in adipocyte growth and/or proliferation.[31] We found that increased methylation at cg21448513 within PLAG1 was negatively associated with cord leptin levels (FDR adjusted p = 0.02). The increased methylation at cg21448513 in PLAG1 may lead to decreased adipocyte proliferation and thus lower cord blood leptin levels.

Table 2. Differentially methylated CpG sites associated with cord blood leptin levels. This table includes the 10 most significant coding genes identified in our EWAS study. See S1 Table for a full list of significant CpG sites associated with cord blood leptin levels.

| Gene   | Gene Name             | Chr | CpG site   | Genomic region | % change in leptin | P          | FDR p'   | Function                                                                 |
|--------|-----------------------|-----|------------|-----------------|-------------------|------------|----------|--------------------------------------------------------------------------|
| RABIF  | RAB Interacting Factor| 1   | cg22388200 | TSS1500         | 45.2              | 2.34E-07   | 0.02     | Regulation of intracellular vesicular transport                         |
| MRPL15 | Mitochondrial Ribosomal Protein L15 | 8 | cg07335376 | TSS1500         | 13.1              | 7.10E-07   | 0.02     | Protein synthesis in mitochondria                                       |
| SMAD3  | SMAD Family Member 3 | 15  | cg03480935 | TSS200          | -8.1              | 7.31E-07   | 0.02     | Transcriptional modulator activated by TGF-beta; regulation of carcinogenesis |
| ITGB2  | Integrin Subunit Beta 2 | 21 | cg13315706 | 5'UTR           | 7.5               | 7.78E-07   | 0.02     | Cell-surface protein that participates in cell adhesion and cell-surface mediated signaling; plays an important role in immune response |
| C2orf84 | Family With Sequence Similarity 228 Member A| 2 | cg26250093 | TSS1500         | 24.5              | 9.08E-07   | 0.02     | Unknown                                                                  |
| C1GALT1 | Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 | 7 | cg22244135 | 5'UTR           | 27.5              | 9.95E-07   | 0.02     | Precursor for extended mucin-type O-glycans on cell surface and secreted glycoproteins |
| SERINC4 | Serine Incorporator 4 | 15  | cg26552774 | TSS200          | 29.7              | 1.18E-06   | 0.02     | Amino acid synthesis and interconversion                                 |
| CCDC155 | Coiled-Coil Domain Containing 155 | 19 | cg04830471 | TSS1500         | -16.5             | 1.26E-06   | 0.02     | Connection between nuclear lamina and cytoskeleton; essential for male and female gametogenesis |
| PLAG1  | Pleiomorphic Adenoma Gene 1 | 8  | cg21448513 | 5'UTR           | -9.4              | 1.36E-06   | 0.02     | Cell proliferation                                                       |
| HSD17B13 | Hydroxysteroid 17-Beta Dehydrogenase 13 | 4 | cg08815403 | TSS200          | -12.8             | 1.41E-06   | 0.02     | Lipoprotein metabolism                                                  |

^Percent change in leptin for every 0.01 increase in methylation beta value
*FDR adjusted p-value

TSS1500: 1500 bp from transcription start site; TSS200: 200 bp from transcription start site; 5'UTR: 5' untranslated region

https://doi.org/10.1371/journal.pone.0226555.t002

Discussion

This epigenome wide association study demonstrates a relationship between neonatal cord blood leptin levels and 1) 247 individual CpG sites and 2) differentially methylated regions of 18 genes. SMAD3, PLAG1, FGF1, HNF4A, DNAJA4, and TFR2 are six genes identified in this study that have previously been reported in relation to tissue growth and adiposity. We chose to highlight these genes for their potential impact on adipose tissue development.

When evaluating associations between individual CpG sites and cord blood leptin levels, four genes are worth noting. SMAD3 encodes for smad3, a signaling effector that mediates transforming growth factor-beta’s (TGF-beta) inhibition of adipocyte differentiation.[30] We identified that increased methylation at cg03480935 within SMAD3 was associated with decreased cord leptin levels. This finding is unexpected as increased methylation is typically associated with decreased gene expression. In this case, potential decreased expression of SMAD3 would lead to less inhibition of adipocyte differentiation and presumably higher leptin levels.

PLAG1 is a transcription factor whose activation results in upregulation of target genes important for cell proliferation. PLAG1 mutations are associated with lipoblastoma, a benign adipocytic tumor, suggesting its role in adipocyte growth and/or proliferation.[31] We found that increased methylation at cg21448513 within PLAG1 was negatively associated with cord leptin levels (FDR adjusted p = 0.02). The increased methylation at cg21448513 in PLAG1 may lead to decreased adipocyte proliferation and thus lower cord blood leptin levels.
Table 3. Differentially methylated CpG regions associated with neonatal cord blood leptin.

| Gene       | Gene Name                     | Chr | DMR location | Genomic Region | # of CpG Sites in DMR | % change in leptin^ | FDR p^ | Function                                                                 |
|------------|-------------------------------|-----|--------------|----------------|-----------------------|---------------------|--------|--------------------------------------------------------------------------|
| TRIM15 /  | TRIM15: Tripartite Motif      | 6   | 3012732–30130109 | 1stExon        | 19                    | -3.9                | 0.0114 | Terminal differentiation of erythroid cells                             |
| TRIM10     | TRIM10: Tripartite Motif      |     |              |                |                       |                     |        |                                                                          |
| PSMB9      | Proteasome Subunit Beta 9     | 6   | 32825040–32826281 | Body           | 15                    | -4.6                | 0.0114 | Immuno-proteasome involved in antigen processing to generate Class I binding peptides |
| CEBPE      | CCAAT/Enhancer Binding Protein Epsilon | 14  | 23586582–23589419 | TSS1500        | 11                    | 5.0                 | 0.0114 | Terminal differentiation and functional maturation of committed granulocyte progenitor cells |
| DNAJA4     | Dnal Heat Shock Protein Family (Hsp40) Member A4 | 15  | 7855907–7855784 | TSS1500        | 14                    | -3.2                | 0.0114 | Heat shock protein                                                       |
| KIF13A     | Kinesin Family Member 13A     | 6   | 17985408–17986167 | Body           | 3                     | -9.4                | 0.0221 | Endosome positioning                                                     |
| DMTN       | Dematin Actin Binding Protein | 8   | 21915184–21917015 | 5'UTR          | 9                     | -4.9                | 0.0291 | Actin binding and bundling protein that plays a structural role in erythrocytes |
| RNF111     | Ring Finger Protein           | 15  | 59156878–59157857 | Intergenic     | 6                     | 4.5                 | 0.0291 | Induction of mesoderm during embryonic development                       |
| MIR451B    | MicroRNA 451B                 | 17  | 27187966–27189879 | TSS1500        | 9                     | -4.7                | 0.0291 | Noncoding RNA involved in mRNA stability and translation                |
| PIK3R5     | Phosphoinositide 3 Kinase     | 17  | 8814822–8816266  | 5'UTR          | 6                     | -10.7               | 0.0313 | Cell growth, proliferation, differentiation, motility, survival, and intracellular trafficking |
| TMEM8A     | Transmembrane Protein 8A      | 16  | 432973–434356   | Body           | 7                     | 6.5                 | 0.0313 | Cell surface adhesion                                                   |
| CCDC88B    | Coiled Cell Domain Containing | 11  | 64107158–64109823 | Body           | 14                    | 4.8                 | 0.0313 | Linking organelles to microtubules                                      |
| CMYA5      | Cardiomyopathy Associated 5   | 5   | 78985425–78986160 | TSS200         | 12                    | 2.1                 | 0.0352 | Anchoring protein Repressor of calcineurin mediated transcriptional activity |
| MIR381HG^2 | Large intergenic non-coding   | 14  | 10151292–101514051 | TSS1500        | 9                     | -2.3                | 0.0358 | Noncoding RNA involved in mRNA stability and translation                |
| KANK2      | KN Motif and Ankyrin Repeat   | 19  | 11305231–11306319 | 5'UTR          | 4                     | 12.4                | 0.0358 | Cytoskeleton formation and regulation of actin polymerization            |
| TFR2       | Transferrin Receptor 2        | 7   | 100230781–100231672 | Body           | 4                     | 6.2                 | 0.0358 | Cellular uptake of transferrin-bound iron                               |
| TSP02      | Translocator Protein 2        | 6   | 4101011–41010728 | Intergenic     | 7                     | -2.2                | 0.0358 | Cholesterol and porphyrin transport; RBC membrane transport             |
| SNORA54^4 / | SNORA5: Small Nucleolar RNA  | 11  | 2985112–2986541  | Body           | 5                     | 0.8                 | 0.0358 | SNORA54: Noncoding RNA NAP1L4: Histone chaperone                        |
| NAP1L4     | H/ACA box 34 NAP1L4: Nucleosome Assembly Protein 1 Like 4 |     |                |                |                       |                     |        |                                                                          |
| SPC7       | Paraplecin Matrix AAA Peptidase Subunit | 16  | 89598305–89598950 | Body           | 3                     | 6.4                 | 0.0358 | Mitochondrial metalloproteinase that plays a role in membrane trafficking, intracellular motility, organelle biogenesis, protein folding, proteolysis |

^Percent change in leptin for every 0.01 increase in methylation beta value and calculated as the inverse-variance weighted average of all CpGs.

^FDR adjusted p-value

^Functions of these genes, especially as they relate to disease, are not well understood.

Hg19 Human Assembly was used to determine DMR locations.

TSS1500: 1500 bp from transcription start site; TSS200: 200 bp from transcription start site; 5'UTR: 5' untranslated region; Body: Gene body; 1stExon: First exon.

https://doi.org/10.1371/journal.pone.0226555.t003
Fig 2. *DNAJA4*: Differentially methylated CpG sites associated with cord blood leptin levels and their relationship to overlapping regulatory elements. The black vertical bars within the gray shaded rectangle represent the differentially methylated CpG sites within the *DNAJA4* promoter that are associated with cord blood leptin levels. For every 0.01 increase in methylation in this region, neonatal leptin decreased by 3.2% (FDR adjusted p = 0.0114). The co-localization of cis-regulatory elements with the *DNAJA4* differentially methylated region are depicted as gray ellipses.

https://doi.org/10.1371/journal.pone.0226555.g002

Fig 3. *TFR2*: Differentially methylated CpG sites associated with cord blood leptin levels and their relationship to overlapping regulatory elements. The black vertical bars within the gray shaded rectangle represent the differentially methylated CpG sites within *TFR2* that, together, are associated with cord blood leptin levels. For every 0.01 increase in methylation in this region, neonatal leptin increased by 6.2% (FDR adjusted p = 0.0358). The co-localization of cis-regulatory elements with *TFR2* differentially methylated region are depicted as gray ellipses.

https://doi.org/10.1371/journal.pone.0226555.g003
FGF1 is another gene clinically important for cell growth and described to have an adipogenic effect.[32] In a mouse model, high fat diet fed mice and the ob/ob mice had higher FGF1 mRNA in their adipose tissue than mice fed a normal diet or lean control mice. [33] We identified that decreased methylation at a CpG site in the FGF1 gene body (cg13724550, FDR adjusted p = 0.0412) is associated with leptin levels.

Lastly, HNF4A is another gene of interest. Increased methylation at a cg16121136 (FDR adjusted p = 0.0307) within the transcription start site was associated with lower leptin levels. Clinically, mutations in HNF4A can cause Mature Onset Diabetes of the Young, Type 1 (MODY1). Further study is necessary to understand the importance of altered methylation at these individual CpG sites on gene expression.

In our analysis of differentially methylated gene regions, DnaJ heat shock protein family (Hsp40) member A4 (DNAJA4) and Transferrin receptor 2 (TFR2) emerged as two interesting genes that have been previously reported in the literature to be associated with tissue growth and adipocytes, respectively.[34, 35] DNAJA4 encodes for a heat shock protein and has been reported to play a role in fetal growth as well as growth of sarcomas.[36, 37] We report that DNAJA4 promoter hypermethylation across 14 CpG sites was negatively associated with neonatal leptin levels, a measure of adiposity. The CpG region identified in our study overlaps with a region previously reported by Roifman, et al in a twin study of placental DNAJA4 methylation and severe growth discordance.[34] While the direction of aberrant methylation and the tissue in which methylation was measured differed from our study, our replication of the same CpG region highlights that this gene region may play a role in the regulation of fetal growth. Our study is the first to report a relationship between cord blood DNAJA4 and leptin, and thus further study into DNAJA4 methylation patterns as they relate to fetal fat tissue accumulation and adipocyte leptin production are necessary.

We also found a positive association of TFR2 hypermethylation and cord blood leptin levels in a region of the gene with multiple overlapping regulatory elements. Given the proximity to regulatory elements, methylation changes in this area may impact gene expression; however, expression analyses are necessary to fully evaluate this possibility. TFR2, expressed primarily in the liver, encodes transferrin receptor 2 which functions as a mediator of cellular uptake of transferrin bound iron. Iron homeostasis has been previously associated with adiposity, perhaps mediated by obesity induced inflammation.[38] In one study of mice fed high fat diets, TFR2 was more highly expressed in adipose tissue compared to mice fed a usual diet.[35] However, the direction of our findings differ from this report, as in our study, increased TFR2 methylation was positively associated with leptin levels. Furthermore, our study is the first to associate TFR2 methylation with a marker of adiposity in a human population. TFR2 may play a role in the regulation of adipose tissue but additional study is needed to fully elucidate these mechanisms.

Using ENCODE, we found multiple regulatory elements overlapping with the DNAJA4 and TFR2 DMRs, suggesting that the significant DMRs are in areas of active gene regulation (Figs 1 and 2). The potential for clinical impact due to altered methylation in these areas is physiologically plausible but without gene expression analyses, we cannot confirm or refute this possibility.

The genes identified in this study are novel in comparison to prior studies of newborn epigenetics and body size. Our previously unreported findings may be accounted for by the fact that the field of newborn epigenetics continues to emerge and evolve and methylation patterns are both tissue and age dependent. Furthermore, this study is not directly comparable to the majority of studies examining newborn methylation and childhood obesity as prior studies have largely focused on outcomes such as birth weight [14, 39] as opposed to anthropometric measures or biomarkers of adiposity or childhood body composition.[11, 12, 40] Pan et al’s
study [13] had a similar aim as ours and identified HIF3A methylation in cord blood to be associated with newborn adiposity. While previously reported genes did not emerge in the current study, the genes we did identify were all implicated in tissue growth, leptin expression or adipocyte development. We propose that altered methylation in these genes lead to impaired adipocyte tissue differentiation and/or growth, thus altering adipocyte mediated leptin production. With more adipose tissue growth, we expect higher leptin production, perhaps inducing a state of leptin resistance, which, in turn is associated with impaired insulin sensitivity, insulin signaling and satiety signaling. [41, 42] Together, these factors can impact energy homeostasis and body composition. While the mechanisms underlying the development of leptin resistance and impact on obesity development are still being elucidated, literature suggests that high leptin levels in obese states are associated with adverse metabolic risk.

Strengths of our study include the use of a cohort of healthy mothers with documented normal glucose tolerance allowing us to remove the well-known confounder of maternal gestational diabetes on fetal adiposity development. In addition, the determination of infant body fat utilized a validated, non-user dependent method contributing to the accuracy and precision of our measurements. Use of the Infinium Illumina 450K array allowed us to examine approximately half a million CpG sites across 99% of RefSeq genes within the genome and identify novel associations.[43] Finally, our DMR analysis helped improve statistical power for detecting weak associations, as neighboring CpGs with similar effects reinforce each other. CpGs have been suggested to not only function individually, but also as a group to impact gene expression.[44] It is also believed that DMRs can control cell-type specific transcriptional repression of an associated gene. DMRcate is a data-driven approach to identify DMRs that can remove the bias incurred from irregularly spaced methylation sites to identify DMRs, which is particularly useful with the design of the Illumina platform and more powerful than other algorithms in detecting DMR where CpG coverage is sparse.

One limitation of our study is our inability to determine the impact that the identified methylation changes have on gene expression due to lack of available RNA. Expression analysis in relevant tissues, such as adipose tissue, is necessary to study the biological plausibility of our reported findings. Our study did not reveal any associations between cord blood gene methylation and direct anthropometric measures of adiposity such as neonatal % body fat, fat mass, and birth weight. Potential explanations for our inability to observe a statistically significant association with newborn fat include our small sample size and inclusion of infants both to women with documented normal glucose tolerance, which removed the well-known confounder of fetal hyperinsulinism and gestational diabetes on newborn macrosomia. [45] However, we did identify epigenetic associations with cord blood leptin levels. In this cohort [46] and others,[47] leptin has been highly correlated with measures of newborn fat and higher levels may impair normal satiety signaling, energy expenditures, and promote the development of insulin resistance.[48] Therefore, the reported associations are notable findings that may reflect subtle, early life changes in a newborn’s metabolic state that may have long term impact on metabolic health. Furthermore, there is little published literature to suggest whether the gene relationships identified in this study play a role in adipose tissue accretion, long term obesity risk or have a significant clinical impact. However, the findings in the DNAJA4, TFR2, PLAG1, and FGF1 genes do suggest a possible underlying physiological mechanism for adipocyte growth mediated by these genes. Additionally, the cross-sectional design of our study only allows us to report associations and we are thus unable to comment on causality or the long-term impact of our findings. Lastly, generalizability is limited given our small sample size and our sole inclusion of mothers with documented normal glucose tolerance during pregnancy.

This study is among the first to examine associations of individual CpG sites and differentially methylated regions in cord blood DNA with cord blood leptin, a marker of neonatal
adiposity. In particular, DNAJA4, TFR2, SMAD3, PLAG1, FGF1 and HNF4A methylation represent novel and possibly physiologically relevant markers of neonatal adiposity. While studies in adults suggest that methylation changes are the consequence of adiposity, the direction in early life and the impact of the in-utero environment is not well characterized. Further study in larger cohorts is necessary to reproduce these our reported findings, elicit how gene methylation is controlled and determine whether these methylation changes impact gene expression. Following a longitudinal cohort over time is also necessary to determine how specific methylation patterns at birth translate to body composition and metabolic risk in childhood and adolescence.

Supporting information

S1 Table. Differentially methylated CpG sites associated with cord blood leptin levels. ^Percent change in leptin for every 0.01 increase in methylation beta value. *SNP containing probes were identified per the Illumina 450K annotation document. Cross-hybridization probes were identified per prior published literature by Chen et al 2013, Epigenetics 8(2):203–209. (PDF)

S2 Table. Evaluated CpG sites in the DNAJA4 and TFR2 genes. ^Percent change in leptin for every 0.01 increase in methylation beta value. *CpG sites that are included in the differentially methylated region (DMR). Hg19 Human Assembly was used to provide DMR location. (PDF)

Acknowledgments

The authors thank Jimmy Ren (Illinois Mathematics and Science Academy) for assistance with gene annotation and gene function search. This study was supported by the National Institutes of Child Health and Human Development Grant K12 HD055884 and a Genentech Growth Disorders Grant G-29954.

Author Contributions

Conceptualization: Rachel Kadakia, Jami L. Josefson.

Data curation: Jami L. Josefson.

Formal analysis: Rachel Kadakia, Yinan Zheng, Zhou Zhang, Wei Zhang, Jami L. Josefson, Lifang Hou.

Funding acquisition: Rachel Kadakia.

Investigation: Rachel Kadakia, Jami L. Josefson.

Methodology: Rachel Kadakia, Yinan Zheng, Jami L. Josefson, Lifang Hou.

Resources: Jami L. Josefson.

Software: Yinan Zheng, Zhou Zhang.

Supervision: Rachel Kadakia, Wei Zhang, Jami L. Josefson, Lifang Hou.

Validation: Wei Zhang.

Visualization: Rachel Kadakia, Yinan Zheng, Zhou Zhang, Wei Zhang.

Writing – original draft: Rachel Kadakia.
Writing – review & editing: Rachel Kadakia, Yinan Zheng, Zhou Zhang, Wei Zhang, Jami L. Josefson, Lifang Hou.

References
1. Catalano PM, Farrell K, Thomas A, Huston-Presley L, Mencin P, de Mouzon SH, et al. Perinatal risk factors for childhood obesity and metabolic dysregulation. Am J Clin Nutr. 2009; 90(5):1303–13. https://doi.org/10.3945/ajcn.2008.27416 PMID: 19759171
2. Ogden CL, Carroll MD, Lawman HG, Fryar CD, Kruszon-Moran D, Kit BK, et al. Trends in Obesity Prevalence Among Children and Adolescents in the United States, 1988–1994 Through 2013–2014. Jama. 2016; 315(21):2292–9. https://doi.org/10.1001/jama.2016.6361 PMID: 27272581
3. Arslanian S. Type 2 diabetes in children: clinical aspects and risk factors. Horm Res. 2002; 57 Suppl 1:19–28.
4. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004; 350(23):2362–74. https://doi.org/10.1056/NEJMoa031049 PMID: 15175438
5. Barker DJ. The fetal and infant origins of adult disease. BMJ. 1990; 301(6761):1111. https://doi.org/10.1136/bmj.301.6761.1111 PMID: 2252919
6. Nicholas LM, Morrison JL, Rattanatray L, Zhang S, Ozanne SE, McMillen IC. The early origins of obesity and insulin resistance: timing, programming and mechanisms. Int J Obes (Lond). 2016; 40(2):229–38.
7. Desai M, Jellyman JK, Ross MG. Epigenomics, gestational programming and risk of metabolic syndrome. Int J Obes (Lond). 2015; 39(4):633–41.
8. El Hajj N, Schneider E, Lehnen H, Haaf T. Epigenetics and life-long consequences of an adverse nutritional and diabetic intrauterine environment. Reproduction. 2014; 148(6):R111–20. https://doi.org/10.1530/REP-14-0334 PMID: 25187623
9. Sharp GC, Salas LA, Monnereau C, Allard C, Yousefi P, Everson TM, et al. Maternal BMI at the start of pregnancy and offspring epigenome-wide DNA methylation: findings from the pregnancy and childhood epigenetics (PACE) consortium. Hum Mol Genet. 2017; 26(20):4067–85. https://doi.org/10.1093/hmg/ddx290 PMID: 29016858
10. Kadakia R, Zheng Y, Zhang Z, Zhang W, Hou L, Josefson JL. Maternal pre-pregnancy BMI downregulates neonatal cord blood LEP methylation. Pediatr Obes. 2016.
11. Godfrey KM, Sheppard A, Gluckman PD, Lillycrop KA, Burdge GC, McLean C, et al. Epigenetic gene promoter methylation at birth is associated with child’s later adiposity. Diabetes. 2011; 60(5):1528–34. https://doi.org/10.2337/db10-0979 PMID: 21471513
12. Sharp GC, Lawlor DA, Richmond RC, Fraser A, Simpkin A, Suderman M, et al. Maternal pre-pregnancy BMI and gestational weight gain, offspring DNA methylation and later offspring adiposity: findings from the Avon Longitudinal Study of Parents and Children. Int J Epidemiol. 2015; 44(4):1288–304. https://doi.org/10.1093/ije/dyv042 PMID: 25855720
13. Pan H, Lin X, Wu Y, Chen L, Teh AL, Soh SE, et al. HIF3A association with adiposity: the story begins before birth. Epigenomics. 2015; 7(6):937–50. https://doi.org/10.2217/epi.15.45 PMID: 26011824
14. Burris HH, Baccarelli AA, Byun HM, Cantoral A, Just AC, Pantic I, et al. Offspring DNA methylation of the aryl-hydrocarbon receptor repressor gene is associated with maternal BMI, gestational age, and birth weight. Epigenetics. 2015; 10(10):913–21. https://doi.org/10.1080/15592294.2015.1078963 PMID: 26252179
15. Agha G, Hajj H, Rifas-Shiman SL, Just AC, Hivert MF, Burris HH, et al. Birth weight-for-gestational age is associated with DNA methylation at birth and in childhood. Clin Epigenetics. 2016; 8:118. https://doi.org/10.1186/s13148-016-0285-3 PMID: 27891191
16. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations with neonatal anthropometrics. Diabetes. 2009; 58(2):453–9. https://doi.org/10.2337/db08-1112 PMID: 19011770
17. Josefson JL, Simons H, Zeiss DM, Metzger BE. Excessive gestational weight gain in the first trimester among women with normal glucose tolerance and resulting neonatal adiposity. J Perinatol. 2016; 36 (12):1034–8. https://doi.org/10.1038/jp.2016.145 PMID: 27583397
18. Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010; 33(3):676–82. https://doi.org/10.2337/dc09-1848 PMID: 20190296
19. Walsh CA, Mahony RT, Foley ME, Daly L, O’Herlihy C. Recurrence of fetal macrosomia in non-diabetic pregnancies. J Obstet Gynaecol. 2007; 27(4):374–8. [10.1080/01443610701327545] PMID: 17654189

20. Ellis KJ, Yao M, Shypailo RJ, Urdal A, Wong WW, Heird WC. Body-composition assessment in infancy: air-displacement plethysmography compared with a reference 4-compartment model. Am J Clin Nutr. 2007; 85(1):90–5. [10.1093/ajcn/85.1.90] PMID: 17209182

21. Ma G, Yao M, Liu Y, Lin A, Zou H, Urdal A, et al. Validation of a new pediatric air-displacement plethysmograph for assessing body composition in infants. Am J Clin Nutr. 2004; 79(4):653–60. [10.1093/ajcn/79.4.653] PMID: 15051611

22. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012; 28(6):882–3. [10.1093/bioinformatics/bts034] PMID: 22057669

23. Michels KB, Binder AM, Dedeurwaerd S, Epstein CB, Greally JM, Gut I, et al. Recommendations for the design and analysis of epigenome-wide association studies. Nat Methods. 2013; 10(10):949–55. [10.1038/nmeth.2632] PMID: 24076989

24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. 1995; 57(1):289–300.

25. Peters TJ, Buckley MJ, Statham AL, Piddley R, Samaras K, R VL, et al. De novo identification of differentially methylated regions in the human genome. Epigenetics & chromatin. 2015; 8:6.

26. Stouffer SA, Suchman EA, DeVinney LC, Star SA, WRM Jr. The American Soldier, Vol. 1: Adjustment During Army Life. Princeton: Princeton University Press; 1949.

27. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 489(7414):57–74. [10.1038/nature11247] PMID: 22955616

28. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44–57. [10.1038/nprot.2008.211] PMID: 19131956

29. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009; 37(1):1–13. [10.1093/nar/gkn923] PMID: 19033363

30. Choy L, Derynck R. Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function. J Biol Chem. 2003; 278(11):9609–19. [10.1074/jbc.M212259200] PMID: 12524424

31. Hibbard MK, Kozakewich HP, Dal Cin P, Sciot R, Tan X, Xiao S, et al. PLAG1 fusion oncogenes in lipoblastoma. Cancer Res. 2000; 60(17):4669–72. PMID: 10987300

32. Hutley L, Shurety W, Newell F, McGearry R, Pelton N, Grant J, et al. Fibroblast growth factor 1: a key regulator of human adipogenesis. Diabetes. 2004; 53(12):3097–106. [10.2337/diabetes.53.12.3097] PMID: 15561939

33. Choi Y, Jang S, Choi MS, Ryoo ZY, Park T. Increased expression of FGF1-mediated signaling molecules in adipose tissue of obese mice. J Physiol Biochem. 2016; 72(2):157–67. [10.1007/s13105-016-0468-6] PMID: 26847131

34. Roifman M, Choufani S, Turinsky AL, Drewlo S, Keating S, Brudno M, et al. Genome-wide placental DNA methylation analysis of severely growth-discordant monochorionic twins reveals novel epigenetic targets for intrauterine growth restriction. Clin Epigenetics. 2016; 8:70. [10.1186/s13148-016-0238-x] PMID: 27330572

35. Gotardo EM, dos Santos AN, Miyashiro RA, Gambero S, Rocha T, Ribeiro ML, et al. Mice that are fed a high-fat diet display increased hepcidin expression in adipose tissue. J Nutr Sci Vitaminol (Tokyo). 2013; 59(5):454–61.

36. Mahoney SE, Yao Z, Keyes CC, Tapscott SJ, Diede SJ. Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas. Epigenetics. 2012; 7(4):400–8. [10.4161/epi.19463] PMID: 22419069

37. Alholle A, Brini AT, Gharanei S, Vaiyapuri S, Arrigoni E, Dallol A, et al. Functional epigenetic approach identifies frequently methylated genes in Ewing sarcoma. Epigenetics. 2013; 8(11):1198–204. [10.4161/epi.26266] PMID: 24005033

38. Becker C, Orozco M, Solomons NW, Schumann K. Iron metabolism in obesity: how interaction between homeostatic mechanisms can interfere with their original purpose. Part I: underlying homeostatic mechanisms of energy storage and iron metabolisms and their interaction. J Trace Elem Med Biol. 2015; 30:195–201. [10.1016/j.jtemb.2014.10.011] PMID: 25467855
39. Gonzalez-Nahm S, Mendez MA, Benjamin-Neelon SE, Murphy SK, Hogan VK, Rowley DL, et al. DNA methylation of imprinted genes at birth is associated with child weight status at birth, 1 year, and 3 years. Clin Epigenetics. 2018; 10:90. https://doi.org/10.1186/s13148-018-0521-0 PMID: 29988473

40. van Dijk SJ, Peters TJ, Buckley M, Zhou J, Jones PA, Gibson RA, et al. DNA methylation in blood from neonatal screening cards and the association with BMI and insulin sensitivity in early childhood. Int J Obes (Lond). 2018; 42(1):28–35.

41. Sainz N, Barrenetxe J, Moreno-Aliaga MJ, Martinez JA. Leptin resistance and diet-induced obesity: central and peripheral actions of leptin. Metabolism. 2015; 64(1):35–46. https://doi.org/10.1016/j.metabol.2014.10.015 PMID: 25497342

42. Dyck DJ, Heigenhauser GJ, Bruce CR. The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity. Acta Physiol (Oxf). 2006; 186(1):5–16.

43. Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA, Bibikova M, et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics. 2011; 6(6):692–702. https://doi.org/10.4161/epi.6.6.16196 PMID: 21593595

44. Bock C. Analysing and interpreting DNA methylation data. Nat Rev Genet. 2012; 13(10):705–19. https://doi.org/10.1038/nrg3273 PMID: 22986265

45. Chu SY, Callaghan WM, Bish CL, D’Angelo D. Gestational weight gain by body mass index among US women delivering live births, 2004–2005: fueling future obesity. American journal of obstetrics and gynecology. 2009; 200(3):271 e1–7.

46. Kadakia R, Zheng Y, Zhang Z, Zhang W, Hou L, Josefson JL. Maternal pre-pregnancy BMI downregulates neonatal cord blood LEP methylation. Pediatr Obes. 2017; 12 Suppl 1:57–64.

47. Geary M, Pringle PJ, Persaud M, Wilshin J, Hindmarsh PC, Rodeck CH, et al. Leptin concentrations in maternal serum and cord blood: relationship to maternal anthropometry and fetal growth. Br J Obstet Gynaecol. 1999; 106(10):1054–60. https://doi.org/10.1111/j.1471-0528.1999.tb08113.x PMID: 10519431

48. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996; 334(5):292–5. https://doi.org/10.1056/NEJM19960201340503 PMID: 8532024